Michael Benatar

25.1k total citations · 2 hit papers
175 papers, 7.8k citations indexed

About

Michael Benatar is a scholar working on Neurology, Genetics and Molecular Biology. According to data from OpenAlex, Michael Benatar has authored 175 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 139 papers in Neurology, 50 papers in Genetics and 26 papers in Molecular Biology. Recurrent topics in Michael Benatar's work include Amyotrophic Lateral Sclerosis Research (83 papers), Neurogenetic and Muscular Disorders Research (48 papers) and Myasthenia Gravis and Thymoma (39 papers). Michael Benatar is often cited by papers focused on Amyotrophic Lateral Sclerosis Research (83 papers), Neurogenetic and Muscular Disorders Research (48 papers) and Myasthenia Gravis and Thymoma (39 papers). Michael Benatar collaborates with scholars based in United States, United Kingdom and Canada. Michael Benatar's co-authors include Joanne Wuu, Martin R. Turner, Gil I. Wolfe, Peter M. Andersen, Donald B. Sanders, Pushpa Narayanaswami, Hiroyuki Murai, Isabel Illa, Henry J. Kaminski and David P. Richman and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Annals of Internal Medicine.

In The Last Decade

Michael Benatar

164 papers receiving 7.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

International consensus guidance for management of myasthenia gravis

2016 710 citations Donald B. Sanders, Gil I. Wolfe et al. Neurology profile →
Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria

2017 590 citations Michael J. Strong, Sharon Abrahams et al. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Benatar United States	47	6.0k	1.9k	1.3k	857	835	175	7.8k
Christopher J. Klein United States	48	3.9k 0.7×	426 0.2×	2.1k 1.6×	1.5k 1.8×	864 1.0×	223	7.3k
John H. J. Wokke Netherlands	56	5.3k 0.9×	1.9k 1.0×	2.0k 1.5×	2.5k 2.9×	1.2k 1.5×	194	8.8k
Lorne Zinman Canada	37	3.0k 0.5×	1.4k 0.7×	1.3k 1.0×	508 0.6×	866 1.0×	126	4.6k
Robert G. Miller United States	46	6.9k 1.2×	3.4k 1.8×	1.5k 1.2×	1.5k 1.8×	1.3k 1.5×	114	9.9k
Arthur P. Hays United States	61	4.8k 0.8×	1.6k 0.8×	3.9k 2.9×	2.8k 3.2×	1.4k 1.7×	170	10.3k
Richard A. Lewis United States	47	4.0k 0.7×	401 0.2×	1.8k 1.3×	3.0k 3.5×	1.0k 1.2×	138	7.4k
Wilson W. Bryan United States	32	2.4k 0.4×	788 0.4×	763 0.6×	798 0.9×	246 0.3×	46	4.1k
David Hilton‐Jones United Kingdom	45	2.7k 0.5×	533 0.3×	2.1k 1.5×	1.2k 1.4×	310 0.4×	142	6.2k
Takamichi Hattori Japan	53	5.2k 0.9×	381 0.2×	870 0.7×	3.0k 3.5×	1.0k 1.2×	308	8.6k
Robert D. Henderson Australia	43	3.0k 0.5×	1.3k 0.7×	727 0.5×	517 0.6×	663 0.8×	228	6.8k

Countries citing papers authored by Michael Benatar

Since Specialization

Citations

This map shows the geographic impact of Michael Benatar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Benatar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Benatar more than expected).

Fields of papers citing papers by Michael Benatar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Benatar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Benatar. The network helps show where Michael Benatar may publish in the future.

Co-authorship network of co-authors of Michael Benatar

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Benatar. A scholar is included among the top collaborators of Michael Benatar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Benatar. Michael Benatar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

O’Brien, David, Kriti Gupta, Thomas Julian, et al.. (2025). Extreme exercise in males is linked to mTOR signalling and onset of amyotrophic lateral sclerosis. Brain. 148(10). 3652–3664. 2 indexed citations

Ferber, Kyle, Erin G. Rosenbaugh, Michael Benatar, et al.. (2025). Measuring neurofilament light in human plasma and cerebrospinal fluid: a comparison of five analytical immunoassays. Clinical Chemistry and Laboratory Medicine (CCLM). 64(2). 410–420.

Wuu, Joanne, Andrea Malaspina, Volkan Granit, et al.. (2025). Skeletal Muscle Biomarkers of Amyotrophic Lateral Sclerosis: A Large‐Scale, Multi‐Cohort Proteomic Study. Annals of Neurology. 99(2). 393–407.

Benatar, Michael, et al.. (2024). Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial. BMJ Neurology Open. 6(1). e000536–e000536. 10 indexed citations

Bampton, Alexander, Caroline McHutchison, Kevin Talbot, et al.. (2024). The Basis of Cognitive and Behavioral Dysfunction in Amyotrophic Lateral Sclerosis. Brain and Behavior. 14(11). e70115–e70115.

Benatar, Michael, Eric A. Macklin, Andrea Malaspina, et al.. (2024). Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis. EBioMedicine. 108. 105323–105323. 14 indexed citations

Rampersaud, Evadnie, Jason R. Myers, Joanne Wuu, et al.. (2024). Genetic Associations With an Amyotrophic Lateral Sclerosis Reversal Phenotype. Neurology. 103(4). e209696–e209696. 2 indexed citations

Benatar, Michael, Hannah Briemberg, Annie Dionne, et al.. (2024). Mismatch between clinically defined classification of ALS stage and the burden of cerebral pathology. Journal of Neurology. 271(5). 2547–2559. 1 indexed citations

Nowak, Richard J., Ari Breiner, Vera Bril, et al.. (2023). Subcutaneous batoclimab in generalized myasthenia gravis: Results from a Phase 2a trial with an open‐label extension. Annals of Clinical and Translational Neurology. 11(1). 194–206. 11 indexed citations

10.

Margolesky, Jason, Corneliu Luca, Henry Moore, et al.. (2023). Blepharoclonus in Parkinsonism. Neurology Clinical Practice. 14(1). e200240–e200240. 1 indexed citations

11.

Heckmann, Jeannine M., Gerrit Botha, Nicola Mulder, et al.. (2023). Analysis of Structural Variants Previously Associated With ALS in Europeans Highlights Genomic Architectural Differences in Africans. Neurology Genetics. 9(4). e200077–e200077. 1 indexed citations

12.

Gonzales, Patrick, Thomas J. LaRocca, Yuping Song, et al.. (2021). Application of a bioinformatic pipeline to RNA-seq data identifies novel virus-like sequence in human blood. G3 Genes Genomes Genetics. 11(9). 5 indexed citations

13.

Benatar, Michael, Joanne Wuu, Peter M. Andersen, et al.. (2018). Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology. 90(7). e565–e574. 101 indexed citations

14.

Hehir, Michael K., Lisa D. Hobson‐Webb, Michael Benatar, et al.. (2017). Rituximab as treatment for anti-MuSK myasthenia gravis. Neurology. 89(10). 1069–1077. 166 indexed citations

15.

Strong, Michael J., Sharon Abrahams, Laura H. Goldstein, et al.. (2017). Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 18(3-4). 153–174. 590 indexed citations breakdown →

16.

Sanders, Donald B., Gil I. Wolfe, Michael Benatar, et al.. (2016). INTERNATIONAL CONSENSUS GUIDANCE FOR THE MANAGEMENT OF MYASTHENIA GRAVIS. Muscle & Nerve. 54. 647–647.

17.

Sanders, Donald B., Gil I. Wolfe, Michael Benatar, et al.. (2016). International consensus guidance for management of myasthenia gravis. Neurology. 87(4). 419–425. 710 indexed citations breakdown →

18.

Turner, Martin R., Orla Hardiman, Michael Benatar, et al.. (2013). Controversies and priorities in amyotrophic lateral sclerosis. The Lancet Neurology. 12(3). 310–322. 385 indexed citations

19.

Benatar, Michael & Rup Tandan. (2011). Reply. Muscle & Nerve. 44(3). 457–457. 1 indexed citations

20.

Benatar, Michael, et al.. (2010). Utility of axial and radial diffusivity from diffusion tensor MRI as markers of neurodegeneration in amyotrophic lateral sclerosis. Brain Research. 1348. 156–164. 104 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact